1. Scrip
  2. >>Business

Asia Executives On The Move: BMS, Pfizer, Takeda, RDPAC

 
• By Brian Yang

Rapid changes in China prompt many pharma companies to shuffle strategies and accelerate personal changes. BMS is getting a new country GM, Pfizer Biopharma China GM is departing and Takeda BU head is stepping down.

Shanghai overpass
MULTINATIONAL DRUG MAKERS SEE MORE EXECUTIVES CHANGES IN CHINA • Source: Shutterstock

Former GSK China executive Siyuan Chen has been appointed as Bristol-Myers Squibb Co.China GM, effective 2 December. Chen was VP and head of respiratory and anti-infectious/HIV business for GlaxoSmithKline PLC China.

Chen succeeds Shirley Zhao who stepped down in June. Since then, BMS Russia GM Marek Vasicek served as the interim...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

More from Scrip

S&E In Brief: Launch Updates And Political Headwinds

 
• By Sushmita Panda

Madrigal and Syndax update investors on their key launches, while Merck KGaA weighs in on the possibility of direct-to-consumer sales in the US.

Another Day Another Win For Novartis’s Ianalumab – This Time In ITP

 
• By Aakash Babu

The Swiss drugmaker’s BAFF-R inhibitor and ADCC-mediated B-cell depletor candidate has chalked up another win in late-stage development, further strengthening its pipeline-in-a-product bid.

Pfizer/Astellas’s Padcev Scores First Big Win In Bladder Cancer Study

 
• By Alaric DeArment

The drug, combined with Merck’s Keytruda, was successful among certain chemotherapy-ineligible MIBC patients, with another Phase III readout expected by March 2026.